AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Illustration showing woman in hybrid workplace sharing her time between an office and working from home remotely

Job Trends

Flexing on the Competition? Smaller Companies Get Higher Marks for Flexibility

Many biopharma professionals view smaller companies as having the best flexibility and remote work options, but that doesn’t mean their larger counterparts are failing in that area. Several professionals, including Apogee Therapeutics and Insmed executives, share their insights.

November 21, 2024

6 min read

Angela Gabriel

Editable vector illustration of a man winning a race. Hi-res jpeg file included.

Editorial

AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’

November 18, 2024

5 min read

Heather McKenzie

Creative process. Pop art collage. Female hand typing on retro typewriter isolated over white background. Vintage, retro 80s, 70s style. Bright colors. Copy space for ad, text

Editorial

Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

November 15, 2024

3 min read

Annalee Armstrong

Podcast

AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.

November 13, 2024

1 min read

Heather McKenzie

Illustration of hand holding trophy with people coming out of trophy and celebrating

Job Trends

BioSpace Announces 2025 Best Places to Work in Biopharma

BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.

November 12, 2024

6 min read

Angela Gabriel

Brain shaped maze. Concept image of study and brain behavior.

Schizophrenia

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.

November 11, 2024

4 min read

Annalee Armstrong

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

November 7, 2024

1 min read

Angela Gabriel

Update: AbbVie headquarters building in California

Earnings

AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.

October 31, 2024

2 min read

Tristan Manalac

Earnings

AbbVie Trims Full-Year Earnings Guidance Due to R&D Milestone Costs

The company is lowering its previously issued guidance for 2024 adjusted earnings per share by $0.04 per share to account for acquired in-process research and development expenses incurred for acquisitions and collaborations in the third quarter.

October 4, 2024

1 min read

Tristan Manalac

JOBS